Open-label, Single-dose, Randomized, Two-way (Two-period) Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80mg) Administered Intravenously in Subjects With Chronic Heart Failure

Trial Profile

Open-label, Single-dose, Randomized, Two-way (Two-period) Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80mg) Administered Intravenously in Subjects With Chronic Heart Failure

Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Furosemide (Primary) ; Furosemide
  • Indications Chronic heart failure
  • Focus Pharmacokinetics; Registrational
  • Sponsors scPharmaceuticals
  • Most Recent Events

    • 20 Sep 2016 According to a scPharmaceuticals media release, data from this study were presented at the 20th Annual Heart Failure Society of America (HFSA) Scientific Meeting 2016.
    • 20 Sep 2016 Results published in a scPharmaceuticals media release.
    • 04 Nov 2015 Positive results published in scPharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top